Private insurers, take a bow. A recent study suggests that your mechanisms for utilization review and management are working to control health care spending better than Medicare, and that the differences are sharply defined.

The study, in the December Health Affairs, is a follow-up to a highly publicized 2009 New Yorker article by Atul Gawande, MD. Gawande compared Medicare spending in McAllen and El Paso, Texas and found higher spending in McAllen. The new study, conducted by Luisa Franzini, PhD, and Osama I. Mikhail, PhD, both from the University of Texas, investigated whether this disparity was present in the non-Medicare populations of those two cities, using medical use and expense data for patients privately insured by Blue Cross & Blue Shield of Texas, the state’s largest commercial insurer.

Given that the same providers who care for Medicare patients usually care for privately insured patients, the researchers wanted to see if the pattern of spending was similar for people under age 65.

Gawande used Medicare measures obtained from the Dartmouth Atlas of Health Care. Those measures were adjusted for age, sex, and race, but not for potential differences in the prices Medicare pays per procedure, or for other variables, such as potential differences in health status across the regions.

Franzini’s study used price-adjusted Medicare claims data, which removes all regional differences in prices to construct a price-neutral index of the use of medical services.

Much like Gawande, Franzini found that Medicare spending in McAllen was 63 percent higher than in El Paso for inpatient care, 32 percent higher for outpatient care, and 65 percent higher for Part B professional services.

Gawande noted these differences between the two cities in his article and attributed them to a change in McAllen during the mid-1990s when providers adopted a more pronounced “entrepreneurial spirit” and a “culture of money.”

But in the younger population — under 65, non-Medicare, and insured by the Blues plan — Franzini found that total spending per member, per year wasn’t much different between the two cities. For several categories of spending, its per-capita costs were actually lower in McAllen.

The implication is that Medicare has minimal utilization management and cannot control the overuse of services that Gawande observed in McAllen, whereas BCBS has more robust UM. It kept the McAllen docs and hospitals in line, it would seem.

Managed Care’s Top Ten Articles of 2016

There’s a lot more going on in health care than mergers (Aetna-Humana, Anthem-Cigna) creating huge players. Hundreds of insurers operate in 50 different states. Self-insured employers, ACA public exchanges, Medicare Advantage, and Medicaid managed care plans crowd an increasingly complex market.

Major health care players are determined to make health information exchanges (HIEs) work. The push toward value-based payment alone almost guarantees that HIEs will be tweaked, poked, prodded, and overhauled until they deliver on their promise. The goal: straight talk from and among tech systems.

They bring a different mindset. They’re willing to work in teams and focus on the sort of evidence-based medicine that can guide health care’s transformation into a system based on value. One question: How well will this new generation of data-driven MDs deal with patients?

The surge of new MS treatments have been for the relapsing-remitting form of the disease. There’s hope for sufferers of a different form of MS. By homing in on CD20-positive B cells, ocrelizumab is able to knock them out and other aberrant B cells circulating in the bloodstream.

A flood of tests have insurers ramping up prior authorization and utilization review. Information overload is a problem. As doctors struggle to keep up, health plans need to get ahead of the development of the technology in order to successfully manage genetic testing appropriately.

Having the data is one thing. Knowing how to use it is another. Applying its computational power to the data, a company called RowdMap puts providers into high-, medium-, and low-value buckets compared with peers in their markets, using specific benchmarks to show why outliers differ from the norm.
Competition among manufacturers, industry consolidation, and capitalization on me-too drugs are cranking up generic and branded drug prices. This increase has compelled PBMs, health plan sponsors, and retail pharmacies to find novel ways to turn a profit, often at the expense of the consumer.
The development of recombinant DNA and other technologies has added a new dimension to care. These medications have revolutionized the treatment of rheumatoid arthritis and many of the other 80 or so autoimmune diseases. But they can be budget busters and have a tricky side effect profile.

Shelley Slade
Vogel, Slade & Goldstein

Hub programs have emerged as a profitable new line of business in the sales and distribution side of the pharmaceutical industry that has got more than its fair share of wheeling and dealing. But they spell trouble if they spark collusion, threaten patients, or waste federal dollars.

More companies are self-insuring—and it’s not just large employers that are striking out on their own. The percentage of employers who fully self-insure increased by 44% in 1999 to 63% in 2015. Self-insurance may give employers more control over benefit packages, and stop-loss protects them against uncapped liability.